RxDoctor Payments Data
★ My doctorsLook up a doctor →

Thomas Iacovoni

Medical · Danville, PANPI 1225262215

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $59,003 of the $71,913 with a category attached, or 82.0%. AbbVie accounts for 72.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $21,901 and has fallen 74.1% since, to $5,675 in 2025. Among medical clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$71,913in general payments, 2019–2025

Across 238 payments — averaging $302.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$52K
  • Alkermes, Inc.$18K
  • Otsuka America Pharmaceutical, Inc.$469
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$388
  • Neurocrine Biosciences, Inc.$264
  • Lundbeck LLC$238
  • plus $175 from 4 others

What the payments were for

  • Consulting fees$2,8004%
  • Speaking & faculty fees$59,00382%
  • Travel & lodging$5,8378%
  • Food & beverage$4,2216%
  • Education$530%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)113$52,380
Alkermes, Inc.51$17,999
Otsuka America Pharmaceutical, Inc.30$469
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)10$388
Neurocrine Biosciences, Inc.12$264
Lundbeck LLC14$238
Vanda Pharmaceuticals Inc.3$72
Teva Pharmaceuticals USA, Inc.2$47
Takeda Pharmaceuticals U.S.A., Inc.2$28
Axsome Therapeutics, Inc.1$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,913 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania →

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl11$15,087
VyvanseLisdexamfetamine Dimesylate12$4,421
Lisdexamfetamine Dimesylate12$1,685
Vilazodone Hcl12$609
Duloxetine Hcl23$498
Escitalopram Oxalate32$267
Zolpidem Tartrate20$148
Quetiapine Fumarate12$118
Lorazepam13$111
Clonazepam11$70

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$52,380$15,08711 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$28$4,42112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Danville

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →